<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00539474</url>
  </required_header>
  <id_info>
    <org_study_id>07/089</org_study_id>
    <secondary_id>ZonMw grant: 80-82310-98-08004</secondary_id>
    <nct_id>NCT00539474</nct_id>
  </id_info>
  <brief_title>&quot;The Efficacy of 'Radioguided Occult Lesion Localization' (ROLL) Versus 'Wire-guided Localization' (WGL) in Breast Conserving Surgery for Non-palpable Breast Cancer: a Randomized Clinical Trial&quot;</brief_title>
  <acronym>ROLL</acronym>
  <official_title>&quot;The Efficacy of 'Radioguided Occult Lesion Localization' (ROLL) Versus 'Wire-guided Localization' (WGL) in Breast Conserving Surgery for Non-palpable Breast Cancer: a Randomized Clinical Trial&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:&#xD;
&#xD;
      Approximately 25% of breast cancers detected are non palpable. Accordingly, a localization&#xD;
      technique is required to help the surgeon to find and remove the cancer. The current&#xD;
      technique (wire guided localization [WGL]) is difficult to perform and has a high rate of&#xD;
      tumour positive margins in the resected specimen, requiring a second operation. A new&#xD;
      approach in the localization and resection of non-palpable malignant breast lesions is 'radio&#xD;
      guided occult lesion localization' (ROLL). ROLL was introduced as a possible replacement for&#xD;
      WGL at the 'European Institute of Oncology' in Milan in 1996. This technique utilizes the&#xD;
      intratumourally injected radiotracer, that is generally used for the lymphatic mapping and&#xD;
      SNB, to localize the primary tumour guided by the gamma probe. Five studies so far have&#xD;
      proven the applicability of this method.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To evaluate the efficacy of Radio Occult Lesion Localisation (ROLL) versus Wire guided&#xD;
      Localisation (WGL) in breast conserving surgery for non-palpable breast cancer&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      A multicenter, prospective randomized clinical trial. Patients with proven non-palpable&#xD;
      breast cancer will be randomized for either ROLL or WGL.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      316 women with a core biopsy proven non palpable cT1 breast carcinoma that are eligible for a&#xD;
      breast conserving treatment and sentinel node biopsy (SNB).&#xD;
&#xD;
      Intervention (if applicable):&#xD;
&#xD;
      Patients in the WGL group will undergo intra tumoural injection of a nuclear radiotracer&#xD;
      under stereotactic or ultrasonographic guidance. After scintigraphic imaging, to monitor the&#xD;
      migration of the radiotracer, a guide wire will be inserted under stereotactic or&#xD;
      ultrasonographic guidance. The excision of the primary tumour is guided by the inserted wire&#xD;
      and the sentinel node procedure is performed using a gamma probe and intratumoural injection&#xD;
      of patent blue.&#xD;
&#xD;
      Patients in the ROLL group will undergo the same procedure except for the guide wire&#xD;
      insertion. The excision of the primary tumour is guided by the gamma probe.&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
      Primary study endpoints; ROLL vs WGL:&#xD;
&#xD;
        1. The percentage of tumour-free margins (invasive and in situ)&#xD;
&#xD;
        2. The volume and maximum diameter of the lumpectomy&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness:&#xD;
&#xD;
      There is no pre-, per- or post operative extra burden. The radiofarmacon is already used in&#xD;
      the standard care of breast cancer patients for the sentinel node biopsy. The used&#xD;
      radio-active substance does not damage the patient.&#xD;
&#xD;
      A specific burden questionnaire, aimed at evaluating the burden of the cosmetic result, will&#xD;
      be administered. To further assess the net impact in terms of Health Related Quality of Life&#xD;
      (HRQoL) also the EQ5D will be obtained at T = 0, 6, 12 and 26 weeks after the initial&#xD;
      diagnostic work-up.&#xD;
&#xD;
      Should the results indicate that overall the WGL procedure lead to better clinical outcome a&#xD;
      cost-effectiveness analysis is foreseen using bootstrapping to assess the uncertainty with&#xD;
      regard to the balance between costs and effects. All analyses will be limited to a half year&#xD;
      time horizon. Accordingly, discounting of costs or effects is not applicable.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radicality, oncologic outcome</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Doctors questionnaires Patients questionnaire cost-effectiveness analysis</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">316</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wireguided localisation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radioguided occult lesion localisation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radio guided occult lesion localisation</intervention_name>
    <description>ROLL procedure using the Europrobe (Europrobe, Strassbourg, France) WGL using a hook wire</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women â‰¥ 18 years, with a non-palpable breast carcinoma (cT1) that need to be treated&#xD;
             with a lumpectomy and sentinel node biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant patients or patients who breast feed&#xD;
&#xD;
          -  Patients with multi focal tumour growth&#xD;
&#xD;
          -  Patients with only ductal carcinoma in situ or lobular carcinoma in situ in the core&#xD;
             biopsy&#xD;
&#xD;
          -  Patients requiring breast amputation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R van Hillegersberg, dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amphia hospital</name>
      <address>
        <city>Breda</city>
        <state>Brabant</state>
        <zip>4800 RK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>st Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3078 HT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>October 3, 2007</study_first_submitted>
  <study_first_submitted_qc>October 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2007</study_first_posted>
  <last_update_submitted>December 22, 2011</last_update_submitted>
  <last_update_submitted_qc>December 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>R. van Hillegersberg</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ROLL trial</keyword>
  <keyword>Minimally invasive surgery</keyword>
  <keyword>Non palpable breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

